Patent intelligence · IL
IL 172160
Method for non-invasive quantification of perfusion in a tissue
Method for non-invasive quantification of perfusion in a tissue
Patent details — IL 172160
- Jurisdiction
- IL
- Status
- granted
- Grant date
- Apr 30, 2015
- Expiration
- Apr 25, 2035
- Applicant
- BRACCO SUISSE SA [CH]
- CPC classes
- A61K 49/ 22 A I, A61K/49223
Quick answer
IL 172160 (Method for non-invasive quantification of perfusion in a tissue) is held by BRACCO SUISSE SA [CH]. Status: granted. Granted Apr 30, 2015. Expires Apr 25, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BRACCO SUISSE SA [CH]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 49/ 22 A I, A61K/49223
More from BRACCO SUISSE SA [CH]
Related pharmaceutical patents in our USPTO index.
-
EP 2117603
TARGETING UND THERAPEUTISCHE VERBINDUNGEN UND GASGEFÜLLTE MIKROVESIKEL MIT DIESEN VERBINDUNGEN
granted -
WO 2009076388
CONJUGUÉS VECTEUR DE CIBLAGE - PHOSPHOLIPIDE
granted -
CA 2670932
DETECTION DU DETACHEMENT D'UN AGENT DE CONTRASTE IMMOBILISE DANS DES APPLICATIONS D'IMAGERIE MEDICALE
granted -
US 2008107607
TARGETING VECTOR-PHOSPHOLIPID CONJUGATES
granted -
US 2008063603
ULTRASOUND CONTRAST AGENTS AND METHODS OF MAKING AND USING THEM
granted -
CA 2631716
CONJUGUES VECTEUR DE CIBLAGE-PHOSPHOLIPIDES
granted -
US 2007128117
Ultrasound contrast agents and process for the preparation thereof
granted
Frequently asked questions
What is US patent 172160?
IL 172160 (Method for non-invasive quantification of perfusion in a tissue) is held by BRACCO SUISSE SA [CH]. Status: granted. Granted Apr 30, 2015. Expires Apr 25, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns IL 172160?
BRACCO SUISSE SA [CH] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does IL 172160 expire?
Our index shows an expiration date of Apr 25, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.